lanifibranor   Click here for help

GtoPdb Ligand ID: 12737

Synonyms: compound 5 [PMID: 29446942] | IVA-337 | IVA337
PDB Ligand
Compound class: Synthetic organic
Comment: Lanifibranor (IVA337) is a pan-peroxisome proliferator-activated receptor (PPAR) agonist that was developed as an antifibrotic clinical lead [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 120.72
Molecular weight 434.92
XLogP 2.05
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES C(CC1=CC2=C(C=CC(=C2)Cl)N1S(=O)(=O)C3=CC4=C(C=C3)N=CS4)CC(=O)O
Isomeric SMILES ClC1=CC=C2N(S(=O)(C3=CC=4SC=NC4C=C3)=O)C(CCCC(O)=O)=CC2=C1
InChI InChI=1S/C19H15ClN2O4S2/c20-13-4-7-17-12(8-13)9-14(2-1-3-19(23)24)22(17)28(25,26)15-5-6-16-18(10-15)27-11-21-16/h4-11H,1-3H2,(H,23,24)
InChI Key OQDQIFQRNZIEEJ-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Lanifibranor (IVA337) is under clinical evaluations for fibrotic diseases, such as non-alcoholic steatohepatitis (NASH) and diffuse scleroderma/systemic sclerosis.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05232071 Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus Phase 2 Interventional Inventiva Pharma
NCT04849728 A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) Phase 3 Interventional Inventiva Pharma
NCT02503644 Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis Phase 2 Interventional Inventiva Pharma
NCT03008070 Phase 2b Study in NASH to Assess IVA337 Phase 2 Interventional Inventiva Pharma 2